Table 3. Responses in 32 NSCLC patients with uncommon EGFR mutations from LUX-Lung 2, LUX-Lung 3 and LUX-Lung 6.

Afatinib treated patients (N=32)	Confirmed responses (N=21)
L861Q (N=12)	7 out of 12 (58%)
G719X (N=8)	6 out of 8 (75%)
S768I + G719X (N=5)	4 out of 5 (80%)
G719X + L861Q (N=3)	2 out of 3 (67%)
S768I + L858R (N=2)	1 out of 2 (50%)
S768I (N=1)	1 out of 1
L861Q + deletion 19 (N=1)	0 out of 1

EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer.